TY - JOUR
T1 - Nucleoprotein vaccine induces cross-protective cytotoxic T lymphocytes against both lineages of influenza B virus
AU - Lee, So Young
AU - Kang, Jung Ok
AU - Chang, Jun
N1 - Publisher Copyright:
© Korean Vaccine Society.
PY - 2019
Y1 - 2019
N2 - Purpose: The influenza B virus diverges into two antigenically distinct lineages: B/Yamagata and B/Victoria. Influenza B is the dominant circulating virus during some influenza seasons, and recent data demonstrated that influenza A and B infection similarly cause severe clinical symptoms in hospitalized patients. Nucleoprotein (NP) is a good target for a universal influenza vaccine. This study investigated whether NP epitope variation within two lineages affects the dominant cytotoxic T lymphocyte (CTL) responses induced by vaccination and the resultant protective immunity. Materials and Methods: The NP of B/Yamagata/16/1988, the representative strain of the Yamagata lineage, includes a dominant CTL epitope, FSPIRITFL, while B/Shangdong/7/1997 from the Victoria lineage has one amino acid difference in this sequence, FSPIRVTFL. Two recombinant replication-deficient adenovirus (rAd)-vectored vaccines expressing either NP were prepared (rAd/B-NP(I) and rAd/B-NP(V), respectively) and administered to BALB/c mice intranasally. To examine the efficacy of vaccination, antibody responses, CTL responses, and morbidity/mortality after challenge were measured. Results: Both vaccines induce similar antibody and CD8 T-cell responses cross-reacting to both epitopes, and also confer cross-protection against both lineages regardless of amino acid difference. Conclusion: The rAd-vectored vaccine expressing the NP could be developed as universal influenza B vaccine which provides broader protection.
AB - Purpose: The influenza B virus diverges into two antigenically distinct lineages: B/Yamagata and B/Victoria. Influenza B is the dominant circulating virus during some influenza seasons, and recent data demonstrated that influenza A and B infection similarly cause severe clinical symptoms in hospitalized patients. Nucleoprotein (NP) is a good target for a universal influenza vaccine. This study investigated whether NP epitope variation within two lineages affects the dominant cytotoxic T lymphocyte (CTL) responses induced by vaccination and the resultant protective immunity. Materials and Methods: The NP of B/Yamagata/16/1988, the representative strain of the Yamagata lineage, includes a dominant CTL epitope, FSPIRITFL, while B/Shangdong/7/1997 from the Victoria lineage has one amino acid difference in this sequence, FSPIRVTFL. Two recombinant replication-deficient adenovirus (rAd)-vectored vaccines expressing either NP were prepared (rAd/B-NP(I) and rAd/B-NP(V), respectively) and administered to BALB/c mice intranasally. To examine the efficacy of vaccination, antibody responses, CTL responses, and morbidity/mortality after challenge were measured. Results: Both vaccines induce similar antibody and CD8 T-cell responses cross-reacting to both epitopes, and also confer cross-protection against both lineages regardless of amino acid difference. Conclusion: The rAd-vectored vaccine expressing the NP could be developed as universal influenza B vaccine which provides broader protection.
KW - Cross protective immunity
KW - Cytotoxic T lymphocytes
KW - Epitope
KW - Influenza B virus
KW - Nucleoproteins
KW - Recombinant adenovirus
UR - http://www.scopus.com/inward/record.url?scp=85062662190&partnerID=8YFLogxK
U2 - 10.7774/cevr.2019.8.1.54
DO - 10.7774/cevr.2019.8.1.54
M3 - Article
AN - SCOPUS:85062662190
SN - 2287-3651
VL - 8
SP - 54
EP - 63
JO - Clinical and Experimental Vaccine Research
JF - Clinical and Experimental Vaccine Research
IS - 1
ER -